Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of lunsekimig (SAR443765) in moderate-to-severe atopic dermatitis
jRCT2031240665Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Mar 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of lunsekimig in atopic dermatitis (AD) (6 arms), sponsored by Sanofi. Primary endpoint: Percent change in EASI score from baseline to Week 24. Started Mar 2025; status: active, not recruiting.
02
Drugs
lunsekimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031240665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240665.